ArticleProceedings of the National Academy of Sciences of the United States of America2019
Successive crystal structure snapshots suggest the basis for MHC class I peptide loading and editing by tapasin.
Open access · bronzeAbstract read
In one paragraph
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- Long-term major histocompatibility complex class I suppression in astronauts and clinical implications.Communications biology · 2026Review
- Engineering high-fidelity tapasin variants to enhance MHC-I antigen presentation.The Journal of biological chemistry · 2026Article
- How conformational changes near the F pocket of MHC class I proteins mediate chaperone assisted peptide loading.Frontiers in immunology · 2025Article
- Tapasin assembly surveillance by the RNF185/Membralin ubiquitin ligase complex regulates MHC-I surface expression.Nature communications · 2024Article
- Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway.Oncogene · 2024Review
- Fast peptide exchange on major histocompatibility complex class I molecules by acidic stabilization of a peptide-empty intermediate.Protein science : a publication of the Protein Society · 2022Article
- Partial peptide dissociation and binding groove plasticity in two major histocompatibility complex class I alleles - differences between allelesRSC advances · 2022Article
- Structural mechanism of tapasin-mediated MHC-I peptide loading in antigen presentation.Nature communications · 2022Article
- Structure of an MHC I-tapasin-ERp57 editing complex defines chaperone promiscuity.Nature communications · 2022Article
- Genetic variation that determinesProceedings of the National Academy of Sciences of the United States of America · 2022Article
- Article
- Article
- Rapid peptide exchange on MHC class I by small molecules elucidates dynamics of bound peptide.Current research in immunology · 2022Article
- Chaperones and Catalysts: How Antigen Presentation Pathways Cope With Biological Necessity.Frontiers in immunology · 2022Review
- The glycosylation status of MHC class I molecules impacts their interactions with TAPBPR.Molecular immunology · 2021Article
- Exchange catalysis by tapasin exploits conserved and allele-specific features of MHC-I molecules.Nature communications · 2021Article
- Dynamics of MHC-I molecules in the antigen processing and presentation pathway.Current opinion in immunology · 2021Review
- TAPBPR promotes antigen loading on MHC-I molecules using a peptide trap.Nature communications · 2021Article
- Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.Frontiers in immunology · 2021Review
- HLA tapasin independence: broader peptide repertoire and HIV control.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 4 countries.
Ida HafstrandScience for Life Laboratory, Department of Medicine Solna, Karolinska Institute, and Division of Infectious Diseases, Karolinska University Hospital, Solna, SE-17176 Stockholm, Sweden.ORCID 0000-0002-1012-9532
Ece Canan SayitogluNova Southeastern University Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33301.
Anca ApavaloaeiDepartment of Life Sciences and Chemistry, Jacobs University Bremen, 28759 Bremen, Germany.ORCID 0000-0001-6896-1199
Benjamin John JoseyNova Southeastern University Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33301.
Renhua SunScience for Life Laboratory, Department of Medicine Solna, Karolinska Institute, and Division of Infectious Diseases, Karolinska University Hospital, Solna, SE-17176 Stockholm, Sweden.ORCID 0000-0002-8203-4946
Xiao HanScience for Life Laboratory, Department of Medicine Solna, Karolinska Institute, and Division of Infectious Diseases, Karolinska University Hospital, Solna, SE-17176 Stockholm, Sweden.ORCID 0000-0003-0879-4119
Sara PellegrinoDepartment of Pharmaceutical Science, General and Organic Chemistry Section, University of Milano, 20133 Italy.
Didem OzkazancNova Southeastern University Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33301.
Renée PotensNova Southeastern University Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33301.
Linda JanssenDepartment of Life Sciences and Chemistry, Jacobs University Bremen, 28759 Bremen, Germany.
Johan NilvebrantDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, AlbaNova University Center, Royal Institute of Technology, SE-10691 Stockholm, Sweden.ORCID 0000-0002-6104-6446
Per-Åke NygrenDepartment of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, AlbaNova University Center, Royal Institute of Technology, SE-10691 Stockholm, Sweden.ORCID 0000-0003-4214-6991
Tatyana SandalovaScience for Life Laboratory, Department of Medicine Solna, Karolinska Institute, and Division of Infectious Diseases, Karolinska University Hospital, Solna, SE-17176 Stockholm, Sweden.
Sebastian SpringerDepartment of Life Sciences and Chemistry, Jacobs University Bremen, 28759 Bremen, Germany.ORCID 0000-0002-5527-6149
Anna-Maria GeorgoudakiNova Southeastern University Cell Therapy Institute, Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Fort Lauderdale, FL 33301.
Adil Doganay DuruScience for Life Laboratory, Department of Medicine Solna, Karolinska Institute, and Division of Infectious Diseases, Karolinska University Hospital, Solna, SE-17176 Stockholm, Sweden.
Adnane AchourScience for Life Laboratory, Department of Medicine Solna, Karolinska Institute, and Division of Infectious Diseases, Karolinska University Hospital, Solna, SE-17176 Stockholm, Sweden; adnane.achour@ki.se.
Karolinska University Hospital · SENova Southeastern University · USConstructor University · DEAlbaNova · SEUniversity of Milan · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
MHC-I epitope presentation to CD8
Indexed as
AnimalsCrystallography, X-RayHEK293 CellsHistocompatibility Antigens Class IHumansLeucineMembrane Transport ProteinsMice, KnockoutModels, MolecularMutationProtein BindingProtein Structure, SecondaryHistocompatibility Antigens Class ILeucineMembrane Transport ProteinstapasinMHC-Ipeptide editingtapasinTAPBPR
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.